Dr. Tripathy Discusses the MONALEESA-7 Trial in HR+ Breast Cancer

Potential in the MONALEESA-7 and MONALEESA-3 TrialsПодробнее

Dr. Tripathy Discusses Key Takeaways from the MONALEESA-7 TrialПодробнее

CDK4/6 Inhibitors in HER2-Negative Breast Cancer Based on Phase III MONALEESA-7 TrialПодробнее

MONALEESA-7: Ribociclib in Premenopausal Women With mBCПодробнее

FDA Approval of Ribociclib for Metastatic Breast CancerПодробнее

Dr. Tripathy on Frontline Endocrine Therapies in HR+ Breast CancerПодробнее

Dr. Varella on the Results of MONALEESA-7 in HR+/HER2- Breast CancerПодробнее

MONALEESA-7 Trial in Premenopausal HR+ Breast CancerПодробнее

Ribociclib plus endocrine therapy improves survival in premenopausal patients with metastatic br...Подробнее

Dr. Burris on Updated MONALEESA-2 Trial Results for HR+ Breast CancerПодробнее

Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast...Подробнее

Dr. Tripathy Discusses HER2 Targeted TherapiesПодробнее

Dr. Tripathy Discusses Breast Cancer BiomarkersПодробнее

Dr. Tripathy Discusses the AVEREL Bevacizumab Trial ResultsПодробнее

Dr. Tripathy on Neoadjuvant Treatment Strategies in HER2+ Breast CancerПодробнее

Endocrine manipulations in premenoupausal metastatic HER2 positive breast cancer: breaking the s...Подробнее

MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine ther...Подробнее

Debu Tripathy, MD discusses the PALOMA-2 trial outcomes in ER+/HER2- advanced breast cancerПодробнее

Dr. Hortobagyi on MONALEESA-2 Trial Results in Breast CancerПодробнее